Vitamin D level in Hungarian patients with inflammatory bowel diseases;D-vitamin-szint mérése hazai gyulladásos bélbetegekben

Orvosi Hetilap

Volumn 154, Issue 46, 2013, Pages 1821-1828

  Lorinczy, Katalin ^a   Lakatos, Péter László ^a   Tóth, Miklós ^a   Salamon, Ágnes ^b   Nemes, Adrienn ^b   Csontos, Ágnes Anna ^a   Fekete, Bálint ^a   Terjék, Orsolya ^a   Herszényi, László ^a   Juhász, Márk ^a   Tulassay, Zsolt ^a   Miheller, Pál ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Belgyógyászati Klinika Budapest ^*  (Hungary)

Author keywords

Colitis ulcerosa; Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; VITAMIN D;

ARTICLE; CROHN DISEASE ACTIVITY INDEX; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

COLITIS ULCEROSA; CROHN'S DISEASE; CROHN-BETEGSÉG; D-VITAMIN; GYULLADÁSOS BÉLBETEGSÉG; INFLAMMATORY BOWEL DISEASES; ULCERATIVE COLITIS; VITAMIN D;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; HUNGARY; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84887782558     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29750     Document Type: Article

References (48)

1. Holick, M. F.: Vitamin D: A millenium perspective. J. Cell. Biochem., 2003, 88, 296-307.
2. Liu, M., Lee, M. H., Cohen, M., et al.: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 1996, 10, 142-153.
3. Christakos, S., Friedlander, E. J., Frandsen, B. R., et al.: Studies on the mode of action of calciferol. XIII. Development of a radioimmunoassay for vitamin D-dependent chick intestinal calcium-binding protein and tissue distribution. Endocrinology, 1979, 104, 1495-1503.
4. Li, Y. C., Kong, J., Wei, M., et al.: 1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest., 2002, 110, 229-238.
5. Favus, M. J. (ed.): Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003. Washington, D. C.: American Society for Bone and Mineral Research. 15:567.
6. Nagpal, S., Na, S., Rathnachalam, R.: Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev., 2005, 26, 662-687.
7. Shikari, M., Kushida, K., Yamazaki, K., et al.: Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr. J., 1996, 43, 211-220.
8. Broe, K. E., Chen, T. C., Weinberg, J., et al.: A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J. Am. Geriatr. Soc., 2007, 55, 234-239.
9. Dukas, L., Schacht, E., Runge, M., et al.: Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittel-Forschung, 2010, 60, 519-525.
10. Li, P., Li, C., Zhao, X., et al.: p27Kip1 stabilization and G1 arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem., 2004, 279, 25260-25267.
11. Zittermann, A.: Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr., 2003, 89, 552-572.
12. Garland, C. F., Comstock, G. W., Garland, F. C., et al.: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet, 1989, 334, 1176-1178.
13. Mathieu, C., Adorini, L.: The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol. Med., 2002, 8, 174-179.
14. Lemire, J. M., Adams, J. S.: 1,25-dihydroxyvitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein-specific T cell clone. J. Bone Miner. Res., 1992, 7, 171-177.
15. Chang, C. C., Ciubotariu, R., Manavalan, J. S., et al.: Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol., 2002, 3, 237-243.
16. Holick, M. F.: Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr., 2004, 79, 362-371.
17. Cantorna, M. T., Munsick, C., Bemiss, C., et al.: 1,25- dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr., 2000, 130, 2648-2652.
18. Cantorna, M. T., Hayes, C. E., DeLuca, H. F.: 1,25- dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J. Nutr., 1998, 128, 68-72.
19. Yuk, J. M., Shin, D. M., Lee, H. M., et al.: Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe, 2009, 6, 231-243.
20. Schauber, J., Rieger, D., Weiler, F., et al.: Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol., 2006, 18, 615-621.
21. Kühn, R., Löhler, J., Rennick, D., et al.: Interleukin-10- deficient mice develop chronic enterocolitis. Cell, 1993, 75, 263-274.
22. MacDonald, T. T.: Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr. Biol., 1994, 4, 261-263.
23. Wada, K., Tanaka, H., Maeda, K., et al.: Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol. Rep., 2009, 22, 1021-1025.
24. Siffledeen, J. S., Siminoski, K., Steinhart, H., et al.: The frequency of vitamin D deficiency in adults with Crohn's disease. Can. J. Gastroenterol., 2003, 17, 473-478.
25. Tajika, M., Matsuura, A., Nakamura, T., et al.: Risk factors for vitamin D deficiency in patients with Crohn's disease. J. Gastroenterol., 2004, 39, 527-533.
26. Jahnsen, J., Falch, J. A., Mowinckel, P., et al.: Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol., 2002, 37, 192-199.
27. Lennard-Jones, J. E.: Classification of inflammatory bowel disease. Scand. J. Gastroenterol., 1989, 170, (Suppl), 2-6.
28. Satsangi, J., Silverberg, M. S., Vermeire, S., et al.: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55, 749-753.
29. Godfrey, K.: Implementation of the Malnutrition Universal Screening Tool. Nurs. Times, 2004, 100, 61.
30. Shivananda, S., Lennard-Jones, J., Logan, R., et al.: Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut, 1996, 39, 690-697.
31. Zeng, L., Anderson, F. H.: Seasonal change in the exacerbations of Crohn's disease. Scand. J. Gastroenterol., 1996, 31, 79-82.
32. Moum, B., Aadland, E., Ekbom, A., et al.: Seasonal variations in the onset of ulcerative colitis. Gut, 1996, 38, 376-378.
33. O'Sullivan, M., O'Morain, C.: Nutrition in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol., 2006, 20, 561-573.
34. Cabré, E., Gassull, M. A.: Nutritional and metabolic issues in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care, 2003, 6, 569-576.
35. Abitbol, V., Roux, C., Guillemant, S., et al.: Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br. J. Surg., 1997, 84, 1551-1554.
36. Ardizzone, S., Bollani, S., Bettica, P., et al.: Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J. Intern. Med., 2000, 247, 63-70.
37. Silvennoinen, J.: Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J. Intern. Med., 1996, 239, 131-137.
38. Bischoff-Ferrari, H. A., Dietrich, T., Orav, E. J., et al.: Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med., 2004, 116, 634-639.
39. Pappa, H. M., Gordon, C. M., Saslowsky, T. M., et al.: Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics, 2006, 118, 1950-1961.
40. Vogelsang, H., Ferenci, P., Resch, H., et al.: Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur. J. Gastroenterol. Hepatol., 1995, 7, 609-614.
41. Bernstein, C. N., Seeger, L. L., Anton, P. A., et al.: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment. Pharmacol. Ther., 1996, 10, 777-786.
42. Miheller, P., Muzes, G., Hritz, I., et al.: Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm. Bowel Dis., 2009, 15, 1656-1662.
43. Leichtmann, G. A., Bengoa, J. M., Bolt, M. J., et al.: Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am. J. Clin. Nutr., 1991, 54, 548-552.
44. Thomas, M. K., Lloyd-Jones, D. M., Thadhani, R. I., et al.: Hypovitaminosis D in medical inpatients. N. Engl. J. Med., 1998, 338, 777-783.
45. Holick, M. F.: Vitamin D deficiency. N. Engl. J. Med., 2007, 357, 266-281.
46. Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., et al.: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011, 96, 1911-1930.
47. Hwang, C., Ross, V., Mahadevan, U.: Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm. Bowel Dis., 2012, 18, 1961-1981.
48. Takács, I., Benko, I., Toldy, E., et al.: Hungarian consensus regarding the role of vitamin D in the prevention and treatment of diseases. [Hazai konszenzus a D-vitamin szerepérol a betegségek megelozésében és kezelésében.] Orv. Hetil., 2012, 153 (Suppl.), 5-26. [Hungarian]